Eric E Smith1, Simon Duchesne2, Fuqiang Gao3, Feryal Saad4, Victor Whitehead5, Cheryl R McCreary6, Richard Frayne7, Serge Gauthier8, Richard Camicioli9, Michael Borrie10, Sandra E Black11. 1. Department of Clinical Neurosciences and Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada. 2. Department of Radiology and Nuclear Medicine, Université Laval, and CERVO Brain Research Center, Québec, Québec, Canada. 3. L.C. Campbell Cognitive Neurology Research Group and Hurvitz Brain Science Research Program, Sunnybrook Research Institute, Toronto, Ontario, Canada. 4. Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada. 5. Lady Davis Institute, Jewish General Hospital, Montreal, Québec, Canada. 6. Departments of Clinical Neurosciences and Radiology, University of Calgary, Calgary, Alberta, Canada. 7. Departments of Radiology and Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary, and Seaman Family MR Research Centre, Foothills Medical Centre, Alberta Health Services, Calgary, Alberta, Canada. 8. McGill Center for Studies in Aging, McGill University, Montreal, Québec, Canada. 9. Neuroscience and Mental Health Institute and Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. 10. Department of Medicine (Geriatric Medicine), Western University, London, Ontario, Canada. 11. Department of Medicine (Neurology), Hurvitz Brain Sciences Research Program, LC Campbell Cognitive Neurology Unit, Canadian Partnership for Stroke Recovery, University of Toronto, London, Ontario, Canada.
Abstract
OBJECTIVE: To describe the neuroimaging and other methods for assessing vascular contributions to neurodegeneration in the Comprehensive Assessment of Neurodegeneration and Dementia (COMPASS-ND) study, a Canadian multi-center, prospective longitudinal cohort study, including reliability and feasibility in the first 200 participants. METHODS: COMPASS-ND includes persons with Alzheimer's disease (AD; n = 150), Parkinson's disease (PD) and Lewy body dementias (LBDs) (200), mixed dementia (200), mild cognitive impairment (MCI; 400), subcortical ischemic vascular MCI (V-MCI; 200), subjective cognitive impairment (SCI; 300), and cognitively intact elderly controls (660). Magnetic resonance imaging (MRI) was acquired according to the validated Canadian Dementia Imaging Protocol and visually reviewed by either of two experienced readers blinded to clinical characteristics. Other relevant assessments include history of vascular disease and risk factors, blood pressure, height and weight, cholesterol, glucose, and hemoglobin A1c. RESULTS: Analyzable data were obtained in 197/200 of whom 18 of whom were clinically diagnosed with V-MCI or mixed dementia. The overall prevalence of infarcts was 24.9%, microbleeds was 24.6%, and high white matter hyperintensity (WMH) was 31.0%. MRI evidence of a potential vascular contribution to neurodegeneration was seen in 12.9%-40.0% of participants clinically diagnosed with another condition such as AD. Inter-rater reliability was good to excellent. CONCLUSION: COMPASS-ND will be a useful platform to study vascular brain injury and its association with risk factors, biomarkers, and cognitive and functional decline across multiple age-related neurodegenerative diseases. Initial findings show that MRI-defined vascular brain injury is common in all cognitive syndromes and is under-recognized clinically.
OBJECTIVE: To describe the neuroimaging and other methods for assessing vascular contributions to neurodegeneration in the Comprehensive Assessment of Neurodegeneration and Dementia (COMPASS-ND) study, a Canadian multi-center, prospective longitudinal cohort study, including reliability and feasibility in the first 200 participants. METHODS: COMPASS-ND includes persons with Alzheimer's disease (AD; n = 150), Parkinson's disease (PD) and Lewy body dementias (LBDs) (200), mixed dementia (200), mild cognitive impairment (MCI; 400), subcortical ischemic vascular MCI (V-MCI; 200), subjective cognitive impairment (SCI; 300), and cognitively intact elderly controls (660). Magnetic resonance imaging (MRI) was acquired according to the validated Canadian Dementia Imaging Protocol and visually reviewed by either of two experienced readers blinded to clinical characteristics. Other relevant assessments include history of vascular disease and risk factors, blood pressure, height and weight, cholesterol, glucose, and hemoglobin A1c. RESULTS: Analyzable data were obtained in 197/200 of whom 18 of whom were clinically diagnosed with V-MCI or mixed dementia. The overall prevalence of infarcts was 24.9%, microbleeds was 24.6%, and high white matter hyperintensity (WMH) was 31.0%. MRI evidence of a potential vascular contribution to neurodegeneration was seen in 12.9%-40.0% of participants clinically diagnosed with another condition such as AD. Inter-rater reliability was good to excellent. CONCLUSION: COMPASS-ND will be a useful platform to study vascular brain injury and its association with risk factors, biomarkers, and cognitive and functional decline across multiple age-related neurodegenerative diseases. Initial findings show that MRI-defined vascular brain injury is common in all cognitive syndromes and is under-recognized clinically.
Authors: Ibrahim Shaikh; Christian Beaulieu; Myrlene Gee; Cheryl R McCreary; Andrew E Beaudin; Diana Valdés-Cabrera; Eric E Smith; Richard Camicioli Journal: Neuroimage Clin Date: 2022-04-04 Impact factor: 4.891